A new study describes a novel cancer-specific protein that is present in a broad range of cancer types and at all stages of tumor development, from premalignant cells to metastatic tumor cells. If verified, the antigen could serve as a marker for the early detection and treatment of primary and metastatic tumors and provide a target for the development of anticancer therapies, including a cancer vaccine.